Nestlé To Develop Immunotherapies For Food Allergies

By: Gáspár Kinga Date: 2022. 07. 20. 11:18

Biopharmaceutical company Enterome has signed a strategic R&D collaboration and license agreement with Nestlé Health Science targeting food allergies and inflammatory bowel disease (IBD).

Nestlé, Enterome Collaboration

Enterome is a clinical stage biopharmaceutical company developing immunomodulatory drugs based on its bacterial Mimicry drug discovery platform. As part of the agreement, Enterome will receive €40 million upfront in cash and equity from Nestlé Health Science. It will also be eligible to receive clinical and sales milestone payments for each licensed therapeutic candidate plus royalties on net sales. Enterome will be responsible for leading drug discovery activities and bear related costs up to the investigational new drug (IND) application.